Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fermenta Biotech Ltd. (FERMENTA.BO)
Mumbai, IN
Fermenta Biotech Ltd. primarily focuses on the creation and provision of Vitamin D3. Their extensive range of offerings includes various forms like crystalline, oil, resin in oil, cold water dispersible (CWD) preparations, and feed-grade powder. These adaptable products are utilized across multiple sectors, such as in pharmaceutical injectables, soft gel capsules, premixes, and for enhancing the nutritional value of food and beverages. The company's business activities are structured into two main divisions: the Chemicals/Bulk Drug segment, which involves the production and sale of chemicals, pharmaceutical ingredients, and enzymes; and the Property segment, dedicated to leasing out real estate. Established on May 1, 1951, by Vijay Kumar Raju Datla, the firm maintains its headquarters in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.89% | -5.08% | -6.55% | -9.88% | +3.73% | -15.75% | -2.23% | +110.25% | -12.19% | +397.20% | +1,781.90% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%+11.6% ★ Q1'26: -14.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-7.4% Q1'26: -47.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+5.9% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+14.6% ★ Q1'26: -1.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+11.9% ★ Q1'26: -1.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.8% ★ Q1'26: +0.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.15× Q1'26: 8.61× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.72B
est: 2.93B (+26.9%)
|
3.98B
est: 3.77B (+5.5%)
|
3.49B
est: 4.53B (-22.8%)
|
3.33B
est: 5.26B (-36.6%)
|
4.69B
est: 5.26B (-10.8%)
|
2.93B
2.93B – 2.93B
-44.3% YoY
|
3.77B
3.77B – 3.77B
+28.8% YoY
|
4.53B
4.53B – 4.53B
+19.9% YoY
|
5.26B
5.26B – 5.26B
+16.3% YoY
|
| EBITDA |
876.08M
est: 444.80M (+97.0%)
|
704.83M
est: 572.97M (+23.0%)
|
-16.85M
est: 687.17M (-102.5%)
|
307.89M
est: 799.09M (-61.5%)
|
1.22B
est: 748.32M (+62.5%)
|
416.54M
416.54M – 416.54M
-44.3% YoY
|
536.57M
536.57M – 536.57M
+28.8% YoY
|
643.51M
643.51M – 643.51M
+19.9% YoY
|
748.32M
748.32M – 748.32M
+16.3% YoY
|
| EBIT |
673.00M
est: 254.17M (+164.8%)
|
359.77M
est: 327.41M (+9.9%)
|
-299.33M
est: 392.66M (-176.2%)
|
60.70M
est: 456.62M (-86.7%)
|
974.00M
est: 419.76M (+132.0%)
|
233.65M
233.65M – 233.65M
-44.3% YoY
|
300.98M
300.98M – 300.98M
+28.8% YoY
|
360.97M
360.97M – 360.97M
+19.9% YoY
|
419.76M
419.76M – 419.76M
+16.3% YoY
|
| Net Income |
455.07M
est: 586.64M (-22.4%)
|
154.47M
est: 450.14M (-65.7%)
|
-510.75M
est: 487.90M (-204.7%)
|
-230.60M
est: 673.76M (-134.2%)
|
768.62M
est: 679.30M (+13.1%)
|
591.46M
591.46M – 591.46M
-12.9% YoY
|
453.84M
453.84M – 453.84M
-23.3% YoY
|
491.90M
491.90M – 491.90M
+8.4% YoY
|
679.30M
679.30M – 679.30M
+38.1% YoY
|
| SGA |
605.53M
est: 370.26M (+63.5%)
|
514.41M
est: 476.95M (+7.9%)
|
296.22M
est: 572.02M (-48.2%)
|
620.80M
est: 665.18M (-6.7%)
|
323.80M
est: 797.24M (-59.4%)
|
443.77M
443.77M – 443.77M
-44.3% YoY
|
571.64M
571.64M – 571.64M
+28.8% YoY
|
685.58M
685.58M – 685.58M
+19.9% YoY
|
797.24M
797.24M – 797.24M
+16.3% YoY
|
| EPS |
15.77
est: 20.20 (-21.9%)
|
5.35
est: 15.50 (-65.5%)
|
-17.70
est: 16.80 (-205.4%)
|
-7.99
est: 23.20 (-134.4%)
|
26.47
est: 23.20 (+14.1%)
|
20.20
20.20 – 20.20
-12.9% YoY
|
15.50
15.50 – 15.50
-23.3% YoY
|
16.80
16.80 – 16.80
+8.4% YoY
|
23.20
23.20 – 23.20
+38.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Prashant Prabhakar Nagre | MD & Additional Director | 71M | male |
| Krishna Vasantkumar Datla | Executive Vice-Chairman | 26M | male |
| Anupama Datla Desai | Executive Director | 18M | female |
| Satish Azad Nadimpally Varma | Executive Director | 18M | male |
| Sahil Desai | Vice President of Business Development & Marketing | — | male |
| Varadvinayak Vijay Khambete | Company Secretary, Compliance Officer, Nodal Officer & Head of Legal | — | male |
| Sumesh Gandhi | Group Chief Financial Officer & President | — | male |
| Uddhav Deshmukh | President of Manufacturing | — | male |
| V. K. Raveendranath | Head of Human Resources & Administration | — | male |
| Prashant Gudhate | President of Corporate Quality Assurance & Regulatory Affairs | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FERMENTA.BO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
